Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other ...

In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy—similar to that ...

After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Researchers at WashU Medicine have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment. Untreated mice develop major scarring ...

Global Cancer Antibody Drug Conjugates Market Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, Oct. 23, 2024 ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell ...

In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Analyst Tim Chiang of Capital One Financial assigned a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of ...